The 2018 APSAD Scientific Program Committee is pleased to announce the Pre-Conference Workshops to be held on Sunday 4 November 2018.
Places are limited, so make sure you sign up during your conference registration.
Already registered and forgot to add your workshop? Contact the conference secretariat at firstname.lastname@example.org and we will add your chosen workshop to your registration.
More information on workshops given below:
|Workshop 1: Hepatitis C in Primary Care and Drug and Alcohol Settings|
|When:||8.30am – 4.30pm|
|Cost:||Free for full conference registrants.
Non-delegates may attend but priority is given to conference attendees.
|Overview:||People who inject drugs represent approximately 90% of newly acquired hepatitis C infections. Clinicians in primary care and drug and alcohol settings play an important role in improving the health outcomes of people living with hepatitis C and can reduce a patient’s risk of developing advanced liver disease through early diagnosis, appropriate management of co-morbidities and treatment with new, curative, Direct Acting Antiviral medication (DAAs).
This interactive course is designed to strengthen the capacity of clinical staff working in primary care or drug and alcohol settings to effectively test for, treat and manage hepatitis C.
The online learning and face-to-face workshop will give you the skills to confidently prescribe the new Direct Acting Antiviral (DAA) medications for hepatitis C.
This course is free. Registration is essential. Lunch and refreshments will be provided.
This activity has been approved by the RACGP QI&CPD Program for 40 Category 1 CPD points.
This Workshop has been supported by Abbvie through Third Party Event Sponsorship and by Gilead through an unrestricted education grant. Sponsorship is governed by our Sponsorship Policy and the sponsor has no control over content, tone, emphasis, allocation of funds or selection of recipients. ASHM does not endorse or promote any sponsor’s product or service.
|Workshop 2: Assessing and Treating Cognitive Impairment in AOD Clients|
|When:||1.00pm – 5.00pm|
|Cost:||Member Rate: AUD $35
Non-Member Rate: AUD $50
| Presenters: |
|Overview:||Definition and Overview of the problem.
Screening tools - MoCA (vs other cog assessment tools).
Model of CI training (BI).
Implementation in practice/evidence of efficacy.
|Workshop 3: Nicotine Update Day – How to Treat a Difficult Case: The New Zealand Way, The Australian Way|
|When:||9.30am – 5.00pm|
|Cost:||Member Rate: AUD $45
Non-Member Rate: AUD $60
|Overview:||A one day workshop containing the most up to date evidence-based treatment, research and clinical practice for smokers.
This workshop will highlight colleague contributions from New Zealand and Australia.
|Morning Session||Chair Renee Bittoun
10.00 - Welcome and Introduction to ASCP - Renee Bittoun
10.30 - Engaging Carers in Quit Smoking Interventions - Louise Ross
1100 - Smoking in pregnancy: links to social and emotional well being, drugs and alcohol in high-priority populations - Gillian Gould
1200 - A protocol for smoking management in Detox Units - Renee Bittoun
|Afternoon Session||Chair Louise Ross
1330 - Smokefree Aotearoa 2025: could calling last orders for smoking in bars help us get there?
Richard Edwards, University of Otago
1500 – Case Study—How Would You Manage This Difficult Case?
Panel: Australia -- Renee Bittoun, Louise Ross; New Zealand--Hayden McRobbie, Natalie Walker, Chris Bullen; Audience participation welcome
1630 – Close
|Workshop 4: Indivior Sponsored Symposium What have we learned from 50 years of opioid agonist treatment?|
|When:||5.30pm – 7.30pm|
|Presenters:||Prof Walter Ling
Dr Grace Wang
Dr Mark Daglish
|Overview:||In 2019 we will reach the milestone of 50 years since the introduction of methadone treatment in Australasia. The introduction of agonist maintenance therapy represented an important shift in understanding of opioid dependence and the objectives of treatment. Over last 50 years our understanding of opioid dependence has developed substantially. Prof Walter Ling has been at the forefront of this development having been involved in foundational research for treatment options and patient centred treatment outcomes. Drawing on many years of research and clinical experience Prof Ling will share his unique perspective on opioid dependence, what we hope to achieve from treatment and how we can measure our success. Treatment options for opioid dependence remain limited however good outcomes can be attained when these options are used well, the second and third speakers will review psychosocial and medical treatments in opioid dependence and how these can be optimised to achieve patient centred outcomes.